Business Daily Media

ACN Business

Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies

  • Written by ACN Newswire - Press Releases

image

TOKYO, Oct 23, 2019 - (JCN Newswire) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease (AD). The Phase 3 EMERGE Study met its primary

Read more //?#

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion